Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2022-12-30
2024-06-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Training Set for the HRD Model in EOC
NCT04651933
A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer
NCT04651920
Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer
NCT04190667
A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration
NCT06564428
NYU Ovarian Cancer Early Detection Program Blood and Genetics
NCT00531778
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Secondary objective: To validate the analytical performance of panel HRD status using WGS HRD status as reference standard.
* Exploratory objective 1: To explore how methylation of selective genes correlate with WGS HRD status and efficacy.
* Exploratory objective 2: To explore how HRR gene mutations correlate with WGS HRD status and efficacy.
* Exploratory objective 3: To set up a harmonized bioinformatic analysis workflow for WGS HRD status.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PARPi
Poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
* High-grade serous or high-grade endometroid histological type
* FIGO stage II, III, or IV
* Complete response or partial response following completion of first-line adjuvant chemotherapy
* PARPi administered as first-line maintenance therapy
Exclusion Criteria
* Total round of first-line chemotherapy (neoadjuvant and adjuvant) less than 5
* First-line PARPi maintenance therapy initiated beyond 12 weeks after last dose of chemotherapy
* Genotyping quality-control failed
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes for Food and Drug Control, China
OTHER
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER
Lei Li
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lei Li
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lei Li
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HRDref-WGS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.